Schedule 13G ownership disclosure
Rocket Pharmaceuticals Inc
Common stock, $0.01 par value per share · CUSIP: 77313F106
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Maverick Capital, Ltd.
Shares: 2,513,110 · Class: 2.3%
- Maverick Capital Management, LLC
Shares: 2,513,110 · Class: 2.3%
- Lee S. Ainslie III
Shares: 2,513,110 · Class: 2.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001012975-26-000137
- Form type
- SCHEDULE 13G/A
- Filer
- MAVERICK CAPITAL LTD
- CIK
- CIK 934639
- Filed
- Feb 13, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership